These findings also suggest that MTHFD2 and potentially other folate synthesis pathway enzymes could potentially be implemented as biomarkers for the use of pemetrexed-based therapy for certain forms of lung carcinoma. This evidence concerns the gene MTHFD2 and lung carcinoma.